Scott Tykodi, MD, PhD
Dr. Scott Tykodi is a member of the Fred Hutchinson Cancer Center's kidney cancer and melanoma program who serves as the Director of Kidney Cancer Research and specializes in the care of kidney cancer patients. Dr. Tykodi is the co-leader of a Kidney Cancer Multispecialty Clinic and oversees a high-dose IL-2 program. He has led more than 30 clinical trials evaluating novel immune-based and targeted therapeutics for patients with kidney cancer or other solid tumors. In addition, Dr. Tykodi has a long-standing collaboration with laboratory based colleagues and participates in pre-clinical studies of T cell immunity targeting kidney cancer.
Financial relationships
-
Attribution:OtherType of financial relationship:Grant Or ContractIneligible company:MerckTopic:clinical researchDate added:03/05/2023Date updated:08/03/2023Relationship end date:10/31/2026
-
Attribution:OtherType of financial relationship:Grant Or ContractIneligible company:AVEO OncologyTopic:clinical researchDate added:03/05/2023Date updated:08/03/2023Relationship end date:04/30/2026
-
Attribution:OtherType of financial relationship:Grant Or ContractIneligible company:Bristol Myers SquibbTopic:clinical researchDate added:03/05/2023Date updated:08/03/2023Relationship end date:06/30/2025
-
Attribution:OtherType of financial relationship:Grant Or ContractIneligible company:ExelixisTopic:clinical researchDate added:03/05/2023Date updated:08/03/2023Relationship end date:05/31/2024
-
Attribution:OtherType of financial relationship:Grant Or ContractIneligible company:PfizerTopic:clinical researchDate added:03/05/2023Date updated:08/03/2023Relationship end date:03/31/2023
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:Bristol Myers SquibbTopic:advisory boardDate added:03/05/2023Date updated:08/03/2023Relationship end date:10/07/2021
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:Targeted OncologyTopic:Regional CME virtual presentationDate added:03/05/2023Date updated:08/03/2023Relationship end date:02/02/2023
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:FirstWordTopic:phone interviewDate added:03/05/2023Date updated:08/03/2023Relationship end date:07/13/2022
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:ExelixisTopic:advisory boardDate added:03/05/2023Date updated:08/03/2023Relationship end date:06/24/2021